These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22720791)

  • 1. Profound thrombocytopenia related with tirofiban: will it be enough to only stop medicine?
    Teke HÜ; Teke D
    Platelets; 2013; 24(4):335-7. PubMed ID: 22720791
    [No Abstract]   [Full Text] [Related]  

  • 2. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
    Dursunoglu D; Taskoylu O; Gür S; Sari I
    Asian Cardiovasc Thorac Ann; 2013 Feb; 21(1):74-6. PubMed ID: 23430426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirofiban-associated acute thrombocytopenia.
    Tuhta AG; Yeşildağ O; Köprülü D
    Acta Cardiol; 2006 Oct; 61(5):577-9. PubMed ID: 17117761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirofiban-induced acute profound thrombocytopenia: what is the optimal approach to treatment?
    Velibey Y; Golcuk Y; Ekmekci A; Altay S; Gunay E; Eren M
    Platelets; 2015; 26(2):197-8. PubMed ID: 23786335
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
    Beiras-Fernandez A; Kowert A; Jiru P; Weis M; Spannagl M; Reichart B; Schmoeckel M
    Ann Thorac Surg; 2009 Feb; 87(2):629-31. PubMed ID: 19161801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia).
    Sakellariou D; Pastromas S; Koulouris S; Manolis AS
    Tex Heart Inst J; 2009; 36(1):55-7. PubMed ID: 19436788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G.
    Clofent-Sanchez G; Harizi H; Nurden A; Coste P; Jais C; Nurden P
    J Thromb Haemost; 2007 May; 5(5):1068-70. PubMed ID: 17461936
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting: is there a paradox?
    Bizzarri F; Frati G
    Ann Thorac Surg; 2009 Sep; 88(3):1048; author reply 1048. PubMed ID: 19699965
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
    Dunkley S; Evans S; Gaudry L; Jepson N
    Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirofiban and emergency coronary surgery.
    Shanmugam G
    Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.